|  |  |  |  |
| --- | --- | --- | --- |
| **Immune-related enterocolitis (irEnterocolitis)** | **Probiotic CBT** ***N*=39** | **No probiotic CBT*****N*=79** |  |
| **irEnterocolitis Grade 1-2, No. (%)** | 2 (5%) | 1 (1%) | *P*＝0.34 |
| **irEnterocolitis Grade 3-4, No. (%)** | 0 (0%) | 2 (3%) |
|  | **Probiotic CBT** ***N*=39** | **No probiotic CBT*****N*=79** |  |
| **Diarrhea during ICI therapya, No. (%)** | 12 (31%) | 22 (28%) | *P*＝0.83 |

**Supplementary Table S1. The relationship between probiotic CBT and the incidence of immune-related enterocolitis/diarrhea during ICI therapy.**

Abbreviation: ICI, immune checkpoint inhibitors; irEnterocoloitis, immune-related enterocolitis; NSCLC, non-small cell lung cancer; probiotic CBT, Probiotic *Clostridium butyricum* therapy. **a**Five patients who had diarrhea during ICI therapy due to endoscopically confirmed immune-related enterocolitis were included in diarrhea during ICI therapy. All events of diarrhea during ICI therapy were grade 1-2 except for two patients who developed endoscopically confirmed immune-related enterocolitis in no probiotic CBT group.